Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = bintrafusp alfa

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
22 pages, 1558 KiB  
Review
Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma
by William R. Britton, Isabel Cioffi, Corinne Stonebraker, Matthew Spence, Ogoegbunam Okolo, Cecilia Martin, Brian Henick, Hiroshi Nakagawa and Anuraag S. Parikh
Cancers 2024, 16(17), 3047; https://doi.org/10.3390/cancers16173047 - 31 Aug 2024
Cited by 3 | Viewed by 3547
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of cancer worldwide according to GLOBOCAN estimates from 2022. Current therapy options for recurrent or metastatic disease are limited to conventional cytotoxic chemotherapy and immunotherapy, with few targeted therapy options readily [...] Read more.
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of cancer worldwide according to GLOBOCAN estimates from 2022. Current therapy options for recurrent or metastatic disease are limited to conventional cytotoxic chemotherapy and immunotherapy, with few targeted therapy options readily available. Recent single-cell transcriptomic analyses identified TGF-β signaling as an important mediator of functional interplays between cancer-associated fibroblasts and a subset of mesenchymal cancer cells. This signaling was shown to drive invasiveness, treatment resistance, and immune evasion. These data provide renewed interest in the TGF-β pathway as an alternative therapeutic target, prompting a critical review of previous clinical data which suggest a lack of benefit from TGF-β inhibitors. While preclinical data have demonstrated the great anti-tumorigenic potential of TGF-β inhibitors, the underwhelming results of ongoing and completed clinical trials highlight the difficulty actualizing these benefits into clinical practice. This topical review will discuss the relevant preclinical and clinical findings for TGF-β inhibitors in HNSCC and will explore the potential role of patient stratification in the development of this therapeutic strategy. Full article
(This article belongs to the Special Issue Molecular Mechanisms in Head and Neck Cancer)
Show Figures

Figure 1

Back to TopTop